Table I.
Patient and tumor characteristics.
| Frequency (n) | % | |
|---|---|---|
| Age | ||
| ≤50 | 23 | 43 |
| >50 | 30 | 57 |
| Tumor stage | ||
| T4abc | 38 | 72 |
| T4d | 15 | 28 |
| Axillary nodes | ||
| cLN0 | 3 | 6 |
| cLN+ | 50 | 94 |
| Hormone receptor status | ||
| ER+/ER− | 28/25 | 53/47 |
| PgR+/PgR− | 17/36 | 32/68 |
| HER2 status | ||
| HER2+ | 10 | 19 |
| HER2− | 43 | 81 |
| Proliferative index | ||
| Ki-67+ | 17 | 32 |
| Ki-67− | 27 | 51 |
| Ki-67 unknown | 9 | 17 |
| Grading | ||
| G2 | 38 | 72 |
| G3 | 15 | 28 |
| Survivin expression | ||
| survivin+ | 21 | 40 |
| survivin− | 32 | 60 |
| p53 expression | ||
| p53+ | 13 | 24 |
| p53− | 40 | 76 |
| survivin+ and p53+ | 11 | 21 |
| survivin− and p53− | 30 | 79 |
ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor receptor 2.